Tatva Chintan Pharma Chem Limited has informed the Exchange regarding Change in Auditors of the company.
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The headline states 'Change in Auditors' but the actual filing does not disclose any change in the Statutory Auditor. The Statutory Auditor remains M/s. NDJ & Co., Chartered Accountants, who issued an unmodified opinion on both Standalone and Consolidated FY2026 results. The filing actually contains three distinct items: (1) Approval of Audited Financial Results for Q4 and FY ended March 31, 2026 — Standalone net profit Rs. 390.82M, Consolidated net profit Rs. 420.54M; (2) Recommendation of Final Dividend of Rs. 2 per share (20%) subject to shareholder approval at AGM; (3) Appointment of M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor for FY2026-27. The headline appears to be a mis-categorisation — no statutory auditor change is disclosed.
No impact from an auditor change. The company reported strong FY2026 results with ~16.7% standalone net profit growth YoY and declared a dividend. The new cost and internal auditor appointments are routine and not alarming.